Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zai Lab On Portfolio Strategy In Post Coronavirus China

Adapting To Changing Oncology Market

Executive Summary

Portfolio management is high on innovative drug maker’s mind amid aftermath of coronavirus outbreak.

You may also be interested in...



Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m

Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.

Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies

Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.

Oncology Progress For BeiGene After Recent Setback

Despite a recent setback for one commercial product in its oncology portfolio, BeiGene is on a roll with another, receiving the second approval in recent months, and the first in a solid tumor, for tislelizumab. The PD-1 contender has also met its endpoint in a first-line lung cancer trial.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel